Cardiovascularis kockázattal rendelkezo páciensek gondozása háziorvosi praxisokban

Dyslipidaemiá páciensek és gondozásuk

Translated title of the contribution: Continuing care of patients with cardiovascular risk in general practices. Patients with dyslipidaemia and their care

Zoltán Jancsó, Z. Varga, Attila Simay, István Ilyés

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: The role of dyslipidaemia is essential in the development of atherosclerosis, therefore continuing care of dyslipidaemic patients is an extremely important task in cardiovascular prevention. Aims: This study was aimed to investigate continuing care of dyslipidaemic patients in general practices. Method of the study was a questionnaire survey, 397 patients of 39 general practices were involved into the study. Results: The cause of their continuing care was hypercholesterolaemia in 91.7%, hypertrigliceridaemia in 69%, decreased HDL-C in 18.4%, and these alterations frequently occurred together. Hypertension in 77%, disturbances of carbohydrate metabolism in 41.7%, increased BMI in 43.2% were found. Patients were smokers in 26.5%, given up smoking in 13.2%. They had cardiovascular problems in 56.5%, cerebrovascular problems in 18.6% and periferial vascular ones in 20.3%. Patients were treated with lipid lowering drugs in 87.7%, statins were used in 81.7%, fibrats in 29.6% and both of them in 11.5%. The main results of continuing care were: in the whole group frequency of cholesterol level > 5.2 mmol/l decreased by 13%, frequency of triglycerid level>1.7 mmol/l decreased by 4%; cholesterol target values were reached in 3% of patients with high cardiovascular risk, in 22.2% of patients with medium risk, and in 66.7% of patients with mild risk. Conclusions: These results suggest that there is a need for more intensive drug treatment of dyslipidaemic patients to reach the target lipid levels, and for regular assessment of continuing care of these patients.

Original languageHungarian
Pages (from-to)2629-2633
Number of pages5
JournalOrvosi Hetilap
Volume146
Issue number52
Publication statusPublished - 2005

Fingerprint

Dyslipidemias
General Practice
Patient Care
Cholesterol
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Carbohydrate Metabolism
Hypercholesterolemia
Pharmaceutical Preparations
Blood Vessels
Atherosclerosis
Smoking
Hypertension

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cardiovascularis kockázattal rendelkezo páciensek gondozása háziorvosi praxisokban : Dyslipidaemiá páciensek és gondozásuk. / Jancsó, Zoltán; Varga, Z.; Simay, Attila; Ilyés, István.

In: Orvosi Hetilap, Vol. 146, No. 52, 2005, p. 2629-2633.

Research output: Contribution to journalArticle

@article{4be56b97159f48c19a353bcb9d5600d7,
title = "Cardiovascularis kock{\'a}zattal rendelkezo p{\'a}ciensek gondoz{\'a}sa h{\'a}ziorvosi praxisokban: Dyslipidaemi{\'a} p{\'a}ciensek {\'e}s gondoz{\'a}suk",
abstract = "Introduction: The role of dyslipidaemia is essential in the development of atherosclerosis, therefore continuing care of dyslipidaemic patients is an extremely important task in cardiovascular prevention. Aims: This study was aimed to investigate continuing care of dyslipidaemic patients in general practices. Method of the study was a questionnaire survey, 397 patients of 39 general practices were involved into the study. Results: The cause of their continuing care was hypercholesterolaemia in 91.7{\%}, hypertrigliceridaemia in 69{\%}, decreased HDL-C in 18.4{\%}, and these alterations frequently occurred together. Hypertension in 77{\%}, disturbances of carbohydrate metabolism in 41.7{\%}, increased BMI in 43.2{\%} were found. Patients were smokers in 26.5{\%}, given up smoking in 13.2{\%}. They had cardiovascular problems in 56.5{\%}, cerebrovascular problems in 18.6{\%} and periferial vascular ones in 20.3{\%}. Patients were treated with lipid lowering drugs in 87.7{\%}, statins were used in 81.7{\%}, fibrats in 29.6{\%} and both of them in 11.5{\%}. The main results of continuing care were: in the whole group frequency of cholesterol level > 5.2 mmol/l decreased by 13{\%}, frequency of triglycerid level>1.7 mmol/l decreased by 4{\%}; cholesterol target values were reached in 3{\%} of patients with high cardiovascular risk, in 22.2{\%} of patients with medium risk, and in 66.7{\%} of patients with mild risk. Conclusions: These results suggest that there is a need for more intensive drug treatment of dyslipidaemic patients to reach the target lipid levels, and for regular assessment of continuing care of these patients.",
keywords = "Cardiovascular risk, Continuing care, Dyslipidaemia",
author = "Zolt{\'a}n Jancs{\'o} and Z. Varga and Attila Simay and Istv{\'a}n Ily{\'e}s",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "2629--2633",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "52",

}

TY - JOUR

T1 - Cardiovascularis kockázattal rendelkezo páciensek gondozása háziorvosi praxisokban

T2 - Dyslipidaemiá páciensek és gondozásuk

AU - Jancsó, Zoltán

AU - Varga, Z.

AU - Simay, Attila

AU - Ilyés, István

PY - 2005

Y1 - 2005

N2 - Introduction: The role of dyslipidaemia is essential in the development of atherosclerosis, therefore continuing care of dyslipidaemic patients is an extremely important task in cardiovascular prevention. Aims: This study was aimed to investigate continuing care of dyslipidaemic patients in general practices. Method of the study was a questionnaire survey, 397 patients of 39 general practices were involved into the study. Results: The cause of their continuing care was hypercholesterolaemia in 91.7%, hypertrigliceridaemia in 69%, decreased HDL-C in 18.4%, and these alterations frequently occurred together. Hypertension in 77%, disturbances of carbohydrate metabolism in 41.7%, increased BMI in 43.2% were found. Patients were smokers in 26.5%, given up smoking in 13.2%. They had cardiovascular problems in 56.5%, cerebrovascular problems in 18.6% and periferial vascular ones in 20.3%. Patients were treated with lipid lowering drugs in 87.7%, statins were used in 81.7%, fibrats in 29.6% and both of them in 11.5%. The main results of continuing care were: in the whole group frequency of cholesterol level > 5.2 mmol/l decreased by 13%, frequency of triglycerid level>1.7 mmol/l decreased by 4%; cholesterol target values were reached in 3% of patients with high cardiovascular risk, in 22.2% of patients with medium risk, and in 66.7% of patients with mild risk. Conclusions: These results suggest that there is a need for more intensive drug treatment of dyslipidaemic patients to reach the target lipid levels, and for regular assessment of continuing care of these patients.

AB - Introduction: The role of dyslipidaemia is essential in the development of atherosclerosis, therefore continuing care of dyslipidaemic patients is an extremely important task in cardiovascular prevention. Aims: This study was aimed to investigate continuing care of dyslipidaemic patients in general practices. Method of the study was a questionnaire survey, 397 patients of 39 general practices were involved into the study. Results: The cause of their continuing care was hypercholesterolaemia in 91.7%, hypertrigliceridaemia in 69%, decreased HDL-C in 18.4%, and these alterations frequently occurred together. Hypertension in 77%, disturbances of carbohydrate metabolism in 41.7%, increased BMI in 43.2% were found. Patients were smokers in 26.5%, given up smoking in 13.2%. They had cardiovascular problems in 56.5%, cerebrovascular problems in 18.6% and periferial vascular ones in 20.3%. Patients were treated with lipid lowering drugs in 87.7%, statins were used in 81.7%, fibrats in 29.6% and both of them in 11.5%. The main results of continuing care were: in the whole group frequency of cholesterol level > 5.2 mmol/l decreased by 13%, frequency of triglycerid level>1.7 mmol/l decreased by 4%; cholesterol target values were reached in 3% of patients with high cardiovascular risk, in 22.2% of patients with medium risk, and in 66.7% of patients with mild risk. Conclusions: These results suggest that there is a need for more intensive drug treatment of dyslipidaemic patients to reach the target lipid levels, and for regular assessment of continuing care of these patients.

KW - Cardiovascular risk

KW - Continuing care

KW - Dyslipidaemia

UR - http://www.scopus.com/inward/record.url?scp=33644852953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644852953&partnerID=8YFLogxK

M3 - Article

VL - 146

SP - 2629

EP - 2633

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 52

ER -